17:18 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Additional study needed for RedHill's Crohn disease candidate

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) said another Phase III trial is "most likely to be required" to support an NDA submission to FDA for Crohn disease candidate RHB-104. On a conference call to discuss data...
22:24 , Jul 30, 2018 |  BC Extra  |  Clinical News

Additional study needed for RedHill's Crohn disease candidate

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) said another Phase III trial is "most likely to be required" to support an NDA submission to FDA for Crohn disease candidate RHB-104. On a conference call Monday to discuss...
22:11 , Jul 5, 2018 |  BC Extra  |  Preclinical News

Antibiotic combos could yield narrow-spectrum therapies

Newly identified synergistic antibiotic combinations could lead to narrow-spectrum therapies for Gram-negative infections, including multidrug resistant (MDR) strains. The research appeared in a Nature article from European Molecular Biology Laboratory (EMBL) and colleagues. The group profiled...
01:22 , Jan 4, 2018 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Synthetic chemistry A photoexcitable catalyst-based method could incorporate deuterium or tritium labels into drug compounds for use in ADME and other assays for measuring drug properties. The method involves reacting a drug compound with a...
01:09 , Dec 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Helicobacter Cell culture and mouse studies suggest an acid-activated antimicrobial peptide could help treat Helicobacter pylori infection without affecting commensal bacteria. The peptide comprises anionic and cationic amino acid residues that adopt a random coiled...
19:27 , Sep 11, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Gas-propelled nanoparticles could be used to deliver therapies to treat stomach infections. The nanoparticles consist of three layers: an outer layer of chitosan polymer for electrostatic adhesion to the gastric mucosa; a middle layer...
19:50 , Aug 18, 2017 |  BC Week In Review  |  Clinical News

DSMB recommends continuation of RedHill's Phase III trial of RHB-104 for CD

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) said an independent DSMB recommend for a second time continuation of the Phase III MAP US trial of RHB-104 to treat Crohn’s disease (CD) based on efficacy and safety...
01:01 , Mar 30, 2017 |  BC Week In Review  |  Clinical News

RHB-104: MAP US2 extension started

RedHill began the open-label, international Phase III MAP US2 extension study to evaluate oral RHB-104 in about 100 patients who have completed 26 weeks of treatment in the double-blind, placebo-controlled, international Phase III MAP US...
02:43 , Jan 25, 2017 |  BC Week In Review  |  Clinical News

RHB-104 regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) and Fast Track designation to RHB-104 from RedHill to treat non-tuberculosis mycobacterial (NTM) infections. The product is a capsule formulation of the generic antibiotics clarithromycin, rifabutin and clofazimine....
22:20 , Jan 4, 2017 |  BC Week In Review  |  Clinical News

RHB-104: Ph III MAP US ongoing

In December, Redhill said an independent DSMB recommended continuation of the double-blind, placebo-controlled, international Phase III MAP US trial of twice-daily oral RHB-104 based on a safety review. The company said MAP US has enrolled...